A new commercially available CEA immunoassay, using monoclonal antibody, was evaluated for the purpose of routine clinical use.
Introduction
The measurement of carcinoembryonic antigen (CEA) in serum has become an important routine Parameter in the postoperative management of certain malignant diseases especially of mammary cancer and of carcinomas of the digestive tract (l, 2, 3) .
In previous years CEA was measured in the authors' laboratory with an enzyme-immunoassay (EIA) from Abbott Diagnostics (Abbott, Amstelveen, The Netherlands) using a polyclonal guinea pig antibody (4, 5) .
A disruption of the supply of this reagent to our country prompted us to consider an alternative mode of assay. Röche Diagnostics (Hoffmann-La Röche, Mijdrecht, The Netherlands) in 1983 introduced a solid phase EIA according to the Sandwich principle. The method uses monoclonal mouse antibody against CEA coated on polystyrene beads. The second antibody is a goat anti-CEA conjugated to peroxidase. o-Phenyle^ediamine serves äs the chromogenic substrate, the resulting colour being spectrophotometrically measured at 492 nm. Because of the limited published literature on this method (6), we investigated the use of this assay for routine clinical application.
Materials and Methods

Patient samples
Blood was taken by punction from an antecubital vein into evacuated blood collecting tubes. The sera were frozen at -20 °C until assay. The samples originated from two hundred and sixty (260) unselected patients for whom a CEA determination had been requested by their physicians.
On one or more occasions, 325 blood samples were collected from the total group.
The patient group consisted of 64% males and 36% of females.
The age ränge of the males was 44-89 years, with an arithmetic mean of 66.1 and a median value of 68.5 years. The age ränge of the females was 24-88 years, with an arithmetic mean of 65.8 and a median value of 66.7 years. A clinical diagnosis was available in 170 cases.
Clinically and histologically proven malignant disease was present in 112 patients (tab. 1).
The remainder showed various pathologies (diverticulitis (n = 10), diverticulosis (n = 5), polyposis coli (n = 3), ulcus ventriculi (n = 2) or no clearly abnormal findings (n = 38)).
CEA assay
The r patient samples were assayed in duplicate by both the polyclonal EIA from Abbott and the new monoclonal EIA from Röche. The detailed instructions of the manufaeturers were followed (tab. 2). Briefiy, both methods consist of a heatinactivation step of the sample followed by the immunological reactions.
Tab. 1. Distribution of carcinomas in the present study. In the Abbott assay use was made of two incubation periods of two hours, in the Röche assay a single overnight incubation step was used. After this incubation the boünd peroxidase label converts the Substrate o-phenylenediamine into 2,2-diaminoazobenzene, which is spectrophotometrically measured at 492 nm.
A calibration graph is prepared by use of the CEA Standards included in each kit.
In order to study the precision of the Röche method three batches of the Röche reagent with different lot numbers (a, b, c) were used. Pools of fresh patient sera were prepared, divided into portions and kept frozen until the assay date at -20 °C.
Within-day precision was obtained by analysis of ten replicate samples of each pool. The concentrations of CEA used are indicated in the ,results section'.
Between-day precision was calculated from the results obtained with two pool sera.
These were assayed in duplicate on ten different days spread over a two-month period together with the control material supplied with the kit. r.
The linearity of the Röche assay was studied by analysing dilutions of 3 human sera with CEA concentrations below 20 §/1. The samples were diluted with the zero Standard of the kit»to 10, 20, 40, 60, 80% of the original concentrations. This consists of a 0.2 mmol/1 acetate bu$er at pH 5.0.
In addition, ten sera of high CEA concentration (approximate ränge 200-1500 g/l) were diluted with the zero Standard. For each sample different degrees of dilution were applied, resulting in concentrations within the measuring ränge.
For instance, suppose one of the sera contained a CEA concentration of 360 g/l. After being diluted twenty, forty and eighty times the sample should ideally show concentrations of 18, 9 and 4.5 g/l respectively. In order to obtain the relative recoveries the concentration calculated by using the largest dilution was arbitrarily taken äs one hundred percent for each sample.
Four of these sera were also diluted with human zero serum in the same way. This zero serum consisted of a pool of samples in which previous assays had shown CEA concentrations less than 0.5 g/l.
Results
Precision of the Röche assay
The coefficient of Variation (CV) for measurement of CEA in the individual tubes within the series ranged between 2.3 and 10%. By taking the square root of these figures the CV for a CEA assay performed in duplicate was obtained. It ranged from 1.5 to 3.2% within the day (tab. 3). 
Linearity of Röche assay
The actual concentrations found for the sera diluted with the zero Standard solution of the kit were plotted against the values theoretically expected (not shown). Linear graphs were obtained within the measuring ränge of the assay (0 -20 g/l).
Furthermore the deviations of the individual points from the graphs were within the precision limits of the assay indicated by table 3.
Sera with high CEA concentrations were diluted to different degrees ranging from 10, 20 and 40 times to 100, 200 and 400 times, in order to achieve values within the measuring ränge.
The various dilutions with the zero Standard of the kit resulted in approximately identical concentrations after correction for the dilution factors applied. The relative recoveries of the diluted samples ranged from 93 to 120%. A mean recovery of 98% ± 9 (l SD) was obtained.
The dilutions with human pool serum yielded lower values for the apparent CEA concentrations in comparison with the same samples diluted with the zero Standard of the kit. The relative recoveries ranged from 83 to 92%. The mean recovery was 89 ± 4% (l SD).
Correlation between Röche monoclonal EIA and Abbott polyclonal EIA Other diagnosis:
T ulcus ventriculi n : n = n : n : n : n = h = 6 13
: 17
: 27 : 5 It can be seen that the line of best fit passes through the origin and, for practical purposes, does not differ from the line described by the relationship y = x.
Six sets of patient data were not included in figure l because of very high vahies for CEA. These were A subdivision into known types of carcinomas is presented in figure 2 . The CEA levels above 10 g/l are given separately in table 6.
Visual inspection of the data shows no systenaatic overall difference between the polyclonal and monoclonal assay for any type of tumour. The differences between the two assays in the individual patient were consistent with time. Thus the Röche method yielded either lower, the same or higher values, compared with the Abbott method ( fig. 3) Fig. 3 . Typical plots of CEA concentrations in varipus cases of pathology followed against time. The differences between the two methods can be seen to be consistent within individual patients.
-Abbott assay o-o Röche assay Case Ä: patient with adenpcarcinoma öf stomach. At first subtotal stomach resection was applied fpr, followed by chemotherapy. Ät the end, progressive disease with metastases to liver and lymph nodes is present. Case B: patient with adenocarcinoma pf stomach. Status after partial resection and adjuvant chemotherapy. Progressive disease. Case C: patient with adenocarcinoma of coecum, for which a hemicolectomy was performed in the past. Guided by rising CEA level, a right liver lobe metastase was found. The CEA level feil after metastasectomy. Case D: patient with epidermoid cell carcinoma of cervix and endometrium with lymph metastases. Treatment with cytostatic agents and radiation therapy. Case E: patient with adenocarcinoma of right lung. Status after lobectomy.
Discussion
A coefficient of Variation of 5% was found with the Röche assay. This between-day reproducibility compares favourably with previously published data on CEA assays. CVs of 5 -15% have been reported (4, 5, 7) . . This good precision may be explained in part by the high actual absorbance values obtained during the spectrophotometric measurement. An absorbance of about 1.5 was obtained at a CEA concentration of 20 g/l, compared with about 0.6 in the Abbott assay.
A small but consistent difference was observed between CEA serum values obtained with different diluting fluids. After dilution with human serum, the apparent recovery was about 10% lower than after dilution with acetate buffer, pH 5, from the Röche kit.
This matrix effect may be due to the composition of normal serum or to protein concentration alone. With respect to the latter factor, Kim et al. reported decreasing CEA values when the concentration of bovine serum albumin in their extraction solution was increased to 5 g/l (8) .
Theoretically this has implications in cases of rising CEA levels during the course of the disease. Suppose a patient's CEA level changes from a level below 20 g/l to above this threshold value. The sample is assayed without a diluent below 20 g/l and is diluted with buffer above this level.
Thereföre a discontinuous increase upon the actual increment would occur. However in the opinion of the authors this seems to be no serious disadvantage of the Röche method for routine purposes. Firstly the difference between buffer and serum äs diluting fluids is relatively small, compared with the large increases of CEA concentration actually occurring in progressive disease states, see e.g. figure 3 .
Secondly, the number of patients concerned is relatively small compared with the large group below 20 §/1, e. g. see figure l. Nevertheless more experiments would be necessary to settle this point in detail.
The 45 degree slope of the regression line ( fig. 1 ) implies that there is no systematic bias between the results obtained with the two methods in patient sera. Thereföre we decided to keep the same reference interval (95% confidence limit) for the Röche assay äs in use for the Abbott assay, i. e. up to 4.5 g/l (5).
One of the arguments for changing from an assay using a polyclonal antibody to one with a monoclonal antibody could be the expectation of greater speci-ficity and/or sensitivity for particular types of tumours.
Rogers et al. (9) described a monoclonal antibody with a preference for CEA in the serum of stomach carcinoma patients. Staab reported that the present Röche assay was more specific for CEA isomers from patients with colon carcinoma than the Röche radioimmunoassay with polyclonal antiserum (6).
However Buchegger et al. (10) and Oehr et al. (11) did not observe particular organ specificity with monoclonal anti-CEA antobodies. In our study üo clusters of the data from any classified type of carcinoma were evident ( fig. 2, tab. 6 ).
The only exception was pancreas carcinoma, all our three patients with advanced metastatic disease giving higher CEA levels with the Röche assay. However, in view of the limited number of subjects this aspect needs further study.
The good general correspondence would imply that the assay using monoclonal antibody is no more organ specific than the one using polyclonal antibody.
According to the manufacturer the new double monoclonal Abbott assay correlates favourably with the polyclonal version tested here. Thus, the Röche and Abbott assays currently available should give equivalent overall results.
In individual cases relatively large differences between the two methods can be obtained ( fig. 3 ). For instance case B from figure 3 demons.tjrates that a change of method from Abbott to Röche at 12 months would have falsely led to the conclusion that CEA production had decreased, whereas it is clear that the opposite is true.
This implies that in order to change from one method to another a transition period is necessary in every patient, in order to establish a new baseline. After an appropriate transition period, the monoclonal EIA of Röche has been used without problems äs the routine method for CEA determinations in both authors' laboratories since the summer of 1984.
